Prognostic impact of NLR, PLR, MLR, and SII in gastric cancer patients treated with immune checkpoint inhibitors: A Systematic Review and meta-analysis.
{"title":"Prognostic impact of NLR, PLR, MLR, and SII in gastric cancer patients treated with immune checkpoint inhibitors: A Systematic Review and meta-analysis.","authors":"Cheng-Hsi Yeh, Shih-Ho Wang","doi":"10.1159/000551598","DOIUrl":null,"url":null,"abstract":"<p><p>Gastric cancer remains a significant global health burden, with immune checkpoint inhibitors showing variable effectiveness in treatment outcomes. This systematic review and meta-analysis examined the prognostic significance of hematologic inflammatory indices in advanced gastric cancer patients receiving immune checkpoint inhibitor. We conducted a comprehensive search of PubMed, EMBASE, and Cochrane CENTRAL databases through August 2023, focusing on neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), monocyte-to-lymphocyte ratio (MLR), and systemic immune-inflammation index (SII). Our analysis included eighteen studies encompassing 2,061 patients with advanced gastric cancer undergoing immune checkpoint inhibitor treatment. The meta-analysis demonstrated that elevated pretreatment inflammatory indices were consistently associated with worse clinical outcomes. High NLR showed significant associations with poor overall survival (adjusted HR: 1.73, 95% CI: 1.38-2.17) and progression-free survival (adjusted HR: 2.16, 95% CI: 1.30-3.58). Similarly, elevated PLR correlated with worse overall survival (adjusted HR: 1.77, 95% CI: 1.38-2.25) and progression-free survival (adjusted HR: 1.56, 95% CI: 1.22-1.99). High MLR and SII also demonstrated significant associations with poorer overall survival outcomes. Higher pretreatment NLR, PLR, MLR, and SII were associated with poorer survival in advanced gastric cancer patients receiving immune checkpoint inhibitors, suggesting a potential role for these simple blood-based indices in risk stratification that warrants confirmation in prospective studies.</p>","PeriodicalId":19497,"journal":{"name":"Oncology","volume":" ","pages":"1-31"},"PeriodicalIF":1.9000,"publicationDate":"2026-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000551598","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Gastric cancer remains a significant global health burden, with immune checkpoint inhibitors showing variable effectiveness in treatment outcomes. This systematic review and meta-analysis examined the prognostic significance of hematologic inflammatory indices in advanced gastric cancer patients receiving immune checkpoint inhibitor. We conducted a comprehensive search of PubMed, EMBASE, and Cochrane CENTRAL databases through August 2023, focusing on neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), monocyte-to-lymphocyte ratio (MLR), and systemic immune-inflammation index (SII). Our analysis included eighteen studies encompassing 2,061 patients with advanced gastric cancer undergoing immune checkpoint inhibitor treatment. The meta-analysis demonstrated that elevated pretreatment inflammatory indices were consistently associated with worse clinical outcomes. High NLR showed significant associations with poor overall survival (adjusted HR: 1.73, 95% CI: 1.38-2.17) and progression-free survival (adjusted HR: 2.16, 95% CI: 1.30-3.58). Similarly, elevated PLR correlated with worse overall survival (adjusted HR: 1.77, 95% CI: 1.38-2.25) and progression-free survival (adjusted HR: 1.56, 95% CI: 1.22-1.99). High MLR and SII also demonstrated significant associations with poorer overall survival outcomes. Higher pretreatment NLR, PLR, MLR, and SII were associated with poorer survival in advanced gastric cancer patients receiving immune checkpoint inhibitors, suggesting a potential role for these simple blood-based indices in risk stratification that warrants confirmation in prospective studies.
期刊介绍：
Although laboratory and clinical cancer research need to be closely linked, observations at the basic level often remain removed from medical applications. This journal works to accelerate the translation of experimental results into the clinic, and back again into the laboratory for further investigation. The fundamental purpose of this effort is to advance clinically-relevant knowledge of cancer, and improve the outcome of prevention, diagnosis and treatment of malignant disease. The journal publishes significant clinical studies from cancer programs around the world, along with important translational laboratory findings, mini-reviews (invited and submitted) and in-depth discussions of evolving and controversial topics in the oncology arena. A unique feature of the journal is a new section which focuses on rapid peer-review and subsequent publication of short reports of phase 1 and phase 2 clinical cancer trials, with a goal of insuring that high-quality clinical cancer research quickly enters the public domain, regardless of the trial’s ultimate conclusions regarding efficacy or toxicity.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
